Estimation of patients organ doses and staff exposure during bone scan examination

Ali, Wadah M.; Sulieman, Abdelmoneim; Tamam, Nissren; Boshara, N.; Aldhebaib, Ali; Alkhorayef, M.; Khandaker, Mayeen Uddin; Bradley, D.A.

doi:10.1016/j.radphyschem.2021.109693

Cited by 21 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess the protective measures and anticipated radiation hazards, it is crucial to evaluate the patient's doses for the NMC staff. Our findings were comparable to the studies revealing that given 99mTc-MDP activity during bone imaging (MBq) varied between 740.0 and 1110.0, with scanning often taking place two to five hours following intravenous radiopharmaceutical administration, and the amount of radioactivity administered, the radioactive element, and length of patient contact time all affect the usual dose during skeletal scanning 4,9 . The mean yearly occupational exposures for GxTs, CTTs and Rads groups in this investigation were between 0.27 and 0.51 mSv, which is consistent with our findings 1 .…”

Section: Discussionsupporting

confidence: 86%

Assessment of staff of radiology department annual effective doses during bone scans

Uzair

Khumaini²,

Mahar

et al. 2023

ijhs

View full text Add to dashboard Cite

Background: The most frequent imaging techniques used by NM departments are skeletal scintigraphy and bone scans. To assess the protective measures and the anticipated radiation hazards, it is crucial to evaluate the patient's doses for the NMC staff. Objectives: Current research intended to evaluate the annual effective doses of radiology department’s staff during bone scans and their health hazards due to radiation. Methods: The study was executed at Nuclear Medical Center, in October 2022 and annual effective dose of radiologists were measured implying the two techniques including 99mTc-MDP TLDs, carrying two dose quantities of Hp (10) and Hp (0.07) and GR-200A TLDs (LiF: Mg, Cu, P). Results: Effective dose of operators was evaluated using 99mTc-MDP TLDs, was found that the mean personal equivalent dosimetry of HP 10 was 0.43 (0.12-0.74) and HP 0.07 was 0.52 (0.11-0.76). Relative strength of residual signal for successive readouts of LiF: Mg, Cu, P chips made had mean GR-200A and Ref. 10 of 0.54+0.23 and 3.10+1.12, respectively. Conclusion: The radiographers in all of the X-ray facilities were well aware of radiation safety and the staff's occupational dosages of HP(0.07) and HP (10) were within the recommended limits.

show abstract

Section: Discussionsupporting

confidence: 86%

Assessment of staff of radiology department annual effective doses during bone scans

Uzair

Khumaini²,

Mahar

et al. 2023

ijhs

View full text Add to dashboard Cite

show abstract

“…Table 1 shows the average and diversity of patients' age (years), effective radiation dose (mSv), and administered radiopharmaceutical activity (MBq) per procedure. Whereas the average administered, activity was 750 (440 to 1400) MBq The average administered activity is Previous studies reported the administered activity during bone imaging (MBq) of 99mTc-MDP routinely changes amid 740.0 to 1110.0, with scanning classically executed during two to five hours after intravenous administration of the radiopharmaceutical [8] [9].…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, depending on workload and procedure approach, areas of the body not covered with the leaded apron might be exposed to unavoidable exposure resulted from ionizing radiation sources. According to reports, staff members may receive a wide range of effective doses ranging from 1.0 to 19.0 mSv yearly [8] [10] [17] [18]. The level of exposure is determined by the radionuclide, its activity, and the sort of job that the individual doses within the department [7].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Patient and Staff Annual Effective Doses at a Nuclear Medicine Department during Bone Scans

Mattar¹

2022

OJRad

View full text Add to dashboard Cite

The current research aims to assess the staff and patients' effective doses during Nuclear medicine (NM) bone scans procedures. The administered activity was utilized to quantify the patients' effective doses, while personnel's effective doses were quantified using thermoluminescent detectors (TLD-100). The average administered activity was 650 (440 to 1440) MBq procedures using SPECT gamma camera system. The average annual staff effective dose (mSv) was estimated to be 2.3 (0.1 to 4.9). The typical patient's effective dose was 4.9 (3.6 to 6.0) mSv per procedure. Staff exposure within the yearly effective dose limits. Patients' exposure optimization is required based on patient weight. Estimating staff eye lens doses is suggested to confirm that the yearly effective radiation doses are within the safety range.

show abstract

“…This modality is known to show modest sensitivity for detecting secondary malignancy [11,12]. Regarding the interval of imaging, cost-effectiveness and concerns about radiation exposure should be considered [2]. Pain is a well-known initial symptom in patients with osteosarcomas and Ewing sarcomas that is often ignored, resulting in a delay in treatment [29].…”

Section: Efficacy Of Bone Scan For Surveillancementioning

confidence: 99%

Does the Clinical Presentation of Secondary Osteosarcoma in Patients Who Survive Retinoblastoma Differ From That of Conventional Osteosarcoma and How Do We Detect Them?

Kim

Park

Cho

et al. 2023

Clin Orthop Relat Res

View full text Add to dashboard Cite

Background Osteosarcoma is the most common secondary malignancy among survivors of retinoblastoma. Most previous reports on secondary malignancy of retinoblastoma included all types of secondary malignancies without a focus on osteosarcoma, owing to its rarity. In addition, there are few studies suggesting tools for regular surveillance for early detection. Questions/purposes (1) What are the radiologic and clinical characteristics of secondary osteosarcoma after retinoblastoma? (2) What is the clinical survivorship? (3) Is a radionuclide bone scan a reasonable imaging modality for early detection in patients with retinoblastoma? Methods Between February 2000 and December 2019, we treated 540 patients for retinoblastoma. Twelve patients (six male, six female) subsequently developed an osteosarcoma in the extremities; two of these patients had two sites of osteosarcoma (10 femurs, four tibiae). A Technetium-99m bone scan image was examined annually in all patients for regular surveillance after the treatment of retinoblastoma as per our hospital’s policy. All patients were treated with the same strategy as that used for primary conventional osteosarcoma, namely neoadjuvant chemotherapy, wide excision, and adjuvant chemotherapy. The median follow-up period was 12 years (range 8 to 21 years). The median age at the time of diagnosis of osteosarcoma was 9 years (range 5 to 15 years), and the median interval from retinoblastoma diagnosis to osteosarcoma diagnosis was 8 years (range 5 to 15 years). Radiologic characteristics were assessed with plain radiographs and MRI, while clinical characteristics were assessed through a retrospective review of medical records. For clinical survivorship, we evaluated overall survival, local recurrence-free survival, and metastasis-free survival. We reviewed the results of bone scans and clinical symptoms at the time of diagnosis for osteosarcoma after retinoblastoma. Results In nine of 14 patients, the tumor had a diaphyseal center, and five of the tumors were located at the metaphysis. The femur was the most common site (n = 10), followed by the tibia (n = 4). The median tumor size was 9 cm (range 5 to 13 cm). There was no local recurrence after surgical resection of the osteosarcoma, and the 5-year overall survival rate after the diagnosis of osteosarcoma was 86% (95% CI 68% to 100%). In all 14 tumors, the Technetium bone scan showed increased uptake in the lesions. Ten of 14 tumors were examined in clinic because of patient complaints of pain in the affected limb. Four patients showed no clinical symptoms detected by abnormal uptake on bone scan. Conclusion For unclear reasons, secondary osteosarcomas in patients who were alive after the treatment of retinoblastoma had a slight predilection for the diaphysis of the long bone compared with patients with spontaneous osteosarcoma in other reports. The clinical survivorship of osteosarcoma as a secondary malignancy after retinoblastoma may not be inferior to that of conventional osteosarcoma. Close follow-up with at least yearly clinical assessment and bone scans or other imaging modalities appears to be helpful in detecting secondary osteosarcoma after the treatment of patients with retinoblastoma. Larger multi-institutional studies will be needed to substantiate these observations. Level of Evidence Level IV, therapeutic study.

show abstract

Estimation of patients organ doses and staff exposure during bone scan examination

Cited by 21 publications

References 27 publications

Assessment of staff of radiology department annual effective doses during bone scans

Assessment of staff of radiology department annual effective doses during bone scans

Assessment of Patient and Staff Annual Effective Doses at a Nuclear Medicine Department during Bone Scans

Does the Clinical Presentation of Secondary Osteosarcoma in Patients Who Survive Retinoblastoma Differ From That of Conventional Osteosarcoma and How Do We Detect Them?

Contact Info

Product

Resources

About